WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

wherein:

R^1 is selected from the group consisting of:

(1) C_{1-6}alkyl, unsubstituted or substituted with $-OR^5$ or $-S(O)_2-C_{1-6}$alkyl,

(2) hydrogen,

(3) phenyl, and

(4) benzyl;

R^2 is selected from the group consisting of:

(1) hydrogen,

(2) $R^4-S(O)_p-$,

wherein R^4 is independently selected from the group consisting of:

(a) $-C_{1-6}$alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(b) phenyl, and

(c) benzyl,

(3) $R^4-S(O)_pN(R^5)-$,

wherein R^5 is independently selected from the group consisting of:

(a) hydrogen,

(b) $-C_{1-6}$alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(c) $-C_{3-6}$cycloalkyl which is unsubstituted or substituted with methyl,

(d) phenyl, which is unsubstitued or substituted with halo or methoxy, and

(e) benzyl,

(4) -CN,

(5) -C_{1-6}alkyl-CN,

(6) halogen,

(7)



wherein R^{8a} and R^{8b} are independently selected from the group consisting of:

(a) hydrogen,

(b) -CN,

(c) halo,

(d) -C_{1-6}alkyl,

(e) -O-R^5,

(f) -S-R^5,

(g) -CO_2R^5, and

(h) tetrazolyl,

(8)



wherein n is 1, 2, 3 or 4;

R^3 is selected from the group consisting of:









R^5-R^7-

;

R^{6a}, R^{6b}, and R^{6c} are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,
(3) $-OR^5$,
(4) $-SR^5$, and
(5) $-C_{1-6}$alkyl;

R^7 is selected from the group consisting of a bond, -CH=CH-, -O-, -S-, and -NH-;

R^9 and R^{10} are independently selected from the group consisting of:
(1) hydrogen,
(2) C_{1-6}alkyl, unsubstituted or substituted with -CN or 1-4 halo,
(3) $-C_{3-6}$cycloalkyl,
(4) phenyl, which is unsubstitued or substituted with halo or methoxy, and
(5) benzyl,
or R^9 and R^{10} may be joined together to form a pyrrolidine or piperidine ring which is unsubstituted or substituted with benzyl, $-OR^5$ or 1-4 halo;

m is independently 0, 1, or 2;
p is independently 0, 1, or 2,
and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein R^1 is C_{1-6}alkyl.

3. The compound of Claim 1 wherein R^1 is methyl.

4. The compound of Claim 1 wherein R^1 is ethyl.

5. The compound of Claim 1 wherein R^2 is:

R^4-$S(O)_2$-NR^5-

and wherein R^4 is selected from the group consisting of:
(4) C_{1-6}alkyl,
(5) phenyl, and
(6) benzyl;
R^5 is selected from the group consisting of:
(5) C_{1-6}alkyl,

(6) phenyl,

(7) benzyl, and

(8) hydrogen.

6. The compound of Claim 1 wherein R^3 is:



and wherein R^5 is methyl, R^{6a} is H or F, R^{6b} and R^{6c} are hydrogen.

7. The compound of Claim 1 wherein R^3 is:



8. The compound of Claim 1 wherein R^9 is hydrogen.

9. The compound of Claim 1 wherein R^{10} is $C_{1\text{-}6}$alkyl.

10. The compound of Claim 1 wherein R^{10} is iso-butyl.

11. A compound which is selected from the group consisting of:











and pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 and a pharmaceutically acceptable carrier.

13. A method for inhibition of β-secretase activity in a mammal which comprises administering to the mammal in need thereof a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

14. A method for treating Alzheimer's disease in a patient comprising the administration to the patient of a therapeutically effective amount of the compound of Claim 1 or a pharaceutically acceptable salt thereof.

15. A method for preventing, controlling, ameliorating or reducing the risk of Alzheimer's disease in a patient comprising the administration to the patient of a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.